Draw/line
Home / Compare / Semaglutide vs Liraglutide

Semaglutide vs Liraglutide

Two GLP-1 drugs from the same maker: liraglutide, the earlier daily injection, and semaglutide, the weekly one that largely replaced it. Here is what the head-to-head trial found.

Side-by-side facts · No recommendation · Reviewed

SemaglutideLiraglutideSame for both

SemaglutideLiraglutide
Acts onBothGLP-1 receptor
Brand namesOzempic, Wegovy, RybelsusVictoza, Saxenda
How oftenWeekly injection; daily tabletsDaily injection
Approved forType 2 diabetes; chronic weight managementType 2 diabetes; chronic weight management, including ages 12 and over
Boxed warningBothThyroid C-cell tumors (rodent data)

The head-to-head trial

STEP 8 compared weekly semaglutide with daily liraglutide in 338 adults with overweight or obesity and no diabetes, alongside diet and activity counseling, for 68 weeks. It was published in JAMA in 2022.

Average weight change was -15.8% with semaglutide and -6.4% with liraglutide. Stomach and bowel side effects were reported by 84.1% and 82.7% of participants. The comparison between the two drugs was open-label, and the trial was funded by Novo Nordisk, which makes both.

Key differences

Liraglutide is injected daily. Semaglutide is injected weekly or taken as a daily tablet.

Liraglutide has more than a decade of real-world use. Cases of medullary thyroid cancer have been reported in people taking it since it came to market.

Questions

Is semaglutide the same as liraglutide?

No. Both act on the GLP-1 receptor and come from the same maker, but they are different molecules. Semaglutide lasts long enough to inject weekly; liraglutide is injected daily.

Which works better for weight loss?

In the STEP 8 trial, average weight change at 68 weeks was -15.8% with semaglutide and -6.4% with liraglutide.

Which compound, if any, suits a person is a decision for them and a licensed prescriber. This page compares published facts and does not recommend either.

Sources: JAMA: STEP 8 trial (Rubino et al., 2022); Bariatric News: STEP 8 results; Managed Healthcare Executive: GLP-1 pills; Prime Therapeutics: GLP-1 pipeline update, August 2026; Novo Nordisk: Wegovy and Saxenda safety information; Polsinelli: FDA compounded GLP-1 policy; Novo Nordisk: Wegovy and Saxenda safety information; Ro: GLP-1 safety information.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.